CoChat

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes

Open access
Gastaldelli, Amalia, Repetto, Enrico, Guja, Cristian, Hardy, Elise, Han, Jenny, Jabbour, Serge A., Ferrannini, Ele · 2020 · Diabetes, Obesity and Metabolism
Cited by 82

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Aim: To assess the efficacy of exenatide (EXE) once weekly + dapagliflozin once daily (DAPA) versus each drug alone in reducing biomarkers of fatty liver/steatosis and fibrosis in a post hoc analysis of DURATION‐8, a 104‐week study in 695 patients with type 2 diabetes uncontrolled by metformin monotherapy. Materials and methods: We evaluated the impact of the study treatments on non‐invasive markers of hepatic steatosis (fatty liver index [FLI] and non‐alcoholic fatty liver disease [NAFLD] liver fat score), fibrosis (fibrosis‐4 index [FIB‐4]) and severe fibrosis (NAFLD fibrosis score), along with liver enzymes and insulin resistance, at weeks 28 and 52. All outcomes in this analysis were exploratory, with nominal P values reported. Results: At week 28, biomarkers of fatty liver/steatosis and fibrosis were reduced from baseline in all treatment groups. At week 28, EXE once weekly + DAPA effects for decrease in FLI were stronger than those of EXE once weekly + placebo (PLB; −2.92, 95% confidence interval [CI] −5.11, −0.73; P = 0.0092) or DAPA+PLB (−2.77 [95% CI −4.93, −0.62]; P = 0.0119), and stronger than those of EXE once weekly + PLB at week 52 (−3.23 [95% CI −5.79, −0.68]; P = 0.0134). FIB‐4 showed reduction versus baseline only in the EXE once weekly + DAPA group at both week 28 (−0.06 [95% CI −0.11, −0.01]; P = 0.0135) and week 52 (−0.05 [95% CI −0.09, −0.004]; P = 0.0308). Conclusions: The EXE once weekly + DAPA combination showed stronger effects than EXE once weekly + PLB or DAPA + PLB in ameliorating markers of hepatic steatosis and fibrosis in patients with type 2 diabetes. Prospective trials are needed to validate these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13907

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 23

  1. 10.1136/gutjnl-2017-313884 · DOI · Paper page
  2. 10.2337/dc19-S004 · DOI · Paper page
  3. 10.1111/dme.13540 · DOI
  4. 10.1186/1471-230X-6-33 · DOI · Paper page
  5. 10.1053/j.gastro.2009.06.005 · DOI · Paper page
  6. 10.1002/hep.21496 · DOI · Paper page
  7. 10.1016/j.cgh.2009.05.033 · DOI · Paper page
  8. 10.1016/S2213-8587(18)30154-2 · DOI · Paper page
  9. 10.1111/dom.13520 · DOI · Paper page
  10. 10.1111/hepr.13304 · DOI · Paper page
  11. 10.1016/j.diabres.2018.05.017 · DOI · Paper page
  12. 10.1016/S2213-8587(16)30267-4 · DOI · Paper page
  13. 10.2337/dc18-0680 · DOI · Paper page
  14. Jabbour SA, 2018, DURATION‐8 randomised controlled trial 104‐week results—once‐weekly exenatide (ExQW) plus once‐daily dapagliflozin (DAPA) vs. ExQW or DAPA alone [ADA abstract 104‐LB], Diabetes, 67, LB29
  15. 10.3390/nu7115475 · DOI · Paper page
  16. 10.1002/hep.25539 · DOI · Paper page
  17. 10.1002/hep.28392 · DOI · Paper page
  18. Klem L, 1995, Reading and understanding multivariate statistics, 65
  19. Giugliano D, 2019, Preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta‐analysis of cardiovascular outcome trials and intensive glucose control trials, J Am Heart Assoc, 18, e012356, 10.1161/JAHA.119.012356 · DOI · Paper page
  20. 10.1053/j.gastro.2015.04.005 · DOI · Paper page
  21. 10.1016/S0618-8278(19)30119-7 · doi:10.1016/s0618-8278(19)30119-7
  22. 10.1007/s13300-017-0355-3 · DOI · Paper page
  23. 10.1111/liv.13480 · DOI · Paper page

Cited by

Metadata

Authors
Gastaldelli, A., Repetto, E., Guja, C., Hardy, E., Han, J., Jabbour, S. A., & Ferrannini, E.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2019-12-14
Volume
22
Issue
3
Pages
393-403
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2985060283
Cited by
82
References
11
FWCI
6.13
Type
journal article
Language
en
Open access
hybrid
Funders
AstraZeneca (GPP3)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.